Blood microsampling technologies: Innovations and applications in 2022
Thangavelu et al.
The finding, in our words
Microsampling reduces sample volume, invasiveness, logistics and biohazard risk while improving stability and enabling at-home self-sampling, yet clinical adoption remains slow and requires standardisation and harmonisation to realise its patient-centric and decentralised potential.
A paraphrase to the Library’s standard, never the abstract. The source is one link away and is always the authority.
In AML and CLL, 91% of VAMS venetoclax results fell within 20% of plasma after individualised haematocrit correction; in home sampling, 18 of 21 patients self-sampled independently and 76% of returned samples were analysable, which shows home microsampling is workable, though the authors ask for multicentre validation.
Levens et al., Clinical Pharmacokinetics (paywalled) · source ↗
Guidance on capillary-to-plasma conversion: method- and analyte-specific clinical validation with paired capillary–venous samples before reporting plasma-equivalent results.
Boffel et al., Therapeutic Drug Monitoring (paywalled) · source ↗
The analysis indicates that dried blood spots and volumetric absorptive microsampling enable minimally invasive monitoring of prohibited substances, with volumetric absorptive microsampling offering improved quantitative reliability over traditional dried spots.
Researchers successfully validated an analytical method for measuring creatinine across plasma and volumetric absorptive microsampling devices, demonstrating strong correlation between conventional plasma and dried microsamples. This provides a reliable, patient-centric approach for monitoring kidney function remotely during transplant follow-up.
Kocur et al., European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences (paywalled) · source ↗
In lung and renal transplant recipients, VAMS sampling with LC-MS/MS quantification of mycophenolic acid and tacrolimus showed good linearity and accuracy, and with a haematocrit-adjusted conversion formula achieved clinical agreement in most samples; tacrolimus did not require haematocrit correction. The approach is virtually painless and enables richer sampling for more accurate drug exposure estimates, supporting decentralised therapeutic drug monitoring.
Juan et al., Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques · source ↗